Key oncogenic signaling pathways affecting tumor-infiltrating lymphocytes infiltration in hepatocellular carcinoma: basic principles and recent advances

Front Immunol. 2024 Feb 15:15:1354313. doi: 10.3389/fimmu.2024.1354313. eCollection 2024.

Abstract

The incidence of hepatocellular carcinoma (HCC) ranks first among primary liver cancers, and its mortality rate exhibits a consistent annual increase. The treatment of HCC has witnessed a significant surge in recent years, with the emergence of targeted immune therapy as an adjunct to early surgical resection. Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) has shown promising results in other types of solid tumors. This article aims to provide a comprehensive overview of the intricate interactions between different types of TILs and their impact on HCC, elucidate strategies for targeting neoantigens through TILs, and address the challenges encountered in TIL therapies along with potential solutions. Furthermore, this article specifically examines the impact of oncogenic signaling pathways activation within the HCC tumor microenvironment on the infiltration dynamics of TILs. Additionally, a concise overview is provided regarding TIL preparation techniques and an update on clinical trials investigating TIL-based immunotherapy in solid tumors.

Keywords: TILs preparation; hepatocellular carcinoma (HCC); immunotherapy; signaling pathway; targeting neoantigens; tumor-infiltrating lymphocytes (TILs).

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Hepatocellular* / pathology
  • Humans
  • Immunotherapy, Adoptive
  • Liver Neoplasms* / pathology
  • Lymphocytes, Tumor-Infiltrating
  • Signal Transduction
  • Tumor Microenvironment

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Natural Science Foundation of China (Grants: 81972643) and the Joint Funds of the Southwest Medical University and Luzhou (Grants: 05/00140026, 05/00160006) and Science and Technology Department of Sichuan Province (Grants: 2023NSFSC0717).